Beyond Acetylcholinesterase Inhibitors for Treating Alzheimer's Disease: α7-nAChR Agonists in Human Clinical Trials

Author(s): Patrizia Russo, Alessandra Del Bufalo, Alessandra Frustaci, Massimo Fini, Alfredo Cesario.

Journal Name: Current Pharmaceutical Design

Volume 20 , Issue 38 , 2014

Submit Manuscript
Submit Proposal

Abstract:

The neuronal nicotinic alpha7-acetylcholine receptor (α7-nAChR) is a promising and attractive drug target for improving cognitive deficits in neuropsychiatric and neurological disorders such as Alzheimer's disease (AD). α7-nAChR belongs to the family of ligand gated ion channels. α7-nAChR is expressed in key brain regions (e.g. pre- and frontal cortex, hippocampus). It is involved in essential cognitive functions such as memory, thinking, comprehension, learning capacity, calculation, orientation, language, and judgment. α7-nAChR binds to amyloid peptide (Aβ) inducing either receptor activation or inhibition in an Aβ concentration-dependent mode. Aβ oligomers induce Τ phosphorylation via α7-nAChR activation. α7-nAChR agonists and/or α7-nAChR positive allosteric modulators may be useful in AD therapy. The current review enlightens: (i) α7-nAChR neurobiology, (ii) α7-nAChR role in cognition and (iii) in AD, and (iv) the clinical status of the most promising molecules for the treatment of cognitive dysfunction in AD.

Keywords: alpha7-nAChR neurobiology, alpha7-nAChR role in cognition, Alzheimer's disease, new drugs.

Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 20
ISSUE: 38
Year: 2014
Page: [6014 - 6021]
Pages: 8
DOI: 10.2174/1381612820666140316130720
Price: $58

Article Metrics

PDF: 48